Marker Q1 net loss narrows to $2.4M; MT-601 shows durable CRs in APOLLO trial

Marker Therapeutics, Inc.

Net loss of $2.4M in Q1 2024 vs $4.9M in Q1 2023; cash $11.3M expected to fund into Q4 2025.
Three patients treated with MT-601: 2 complete responses (one >9 months after CAR-T relapse) and 1 partial response; well tolerated.
MT-601 received nonproprietary name 'neldaleucel' from USAN/INN; more data expected H2 2024.
MT-401-OTS IND cleared for AML/MDS; clinical initiation expected H2 2024; secured $2M NIH SBIR funding.
R&D expenses $2.6M, G&A $1.2M, both down YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Marker Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-062001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.